Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KHK | P50053 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.35 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30283054 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CYP1A2CYP2C9CYP2C19NPSR1 | |
| SCHEMBL26121667 | 0.81 | ALDH1A1 (0.41) | ALDH1A1CYP1A2CYP2C9CYP2C19NPSR1 | |
| SCHEMBL31339805 | 0.81 | ALDH1A1 (0.41) | ALDH1A1CYP1A2CYP2C9CYP2C19NPSR1 | |
| SCHEMBL12775196 | 0.78 | KDM5A (0.36) | ALDH1A1CYP1A2CYP2C9CYP2C19NPSR1 | |
| SCHEMBL810776 | 0.77 | KDM4E (0.41) | ALDH1A1KDM4EGAAKHKHTT | |
| SCHEMBL810127 | 0.77 | L3MBTL1 (0.33) | ALDH1A1KDM4ESMN1; SMN2ARPOLB | |
| SCHEMBL531211 | 0.77 | MAPK1 (0.33) | ALDH1A1SMN1; SMN2ARPOLBL3MBTL1 | |
| SCHEMBL5857653 | 0.77 | TRPV4 (0.33) | ALDH1A1SMN1; SMN2ARPOLBL3MBTL1 | |
| SCHEMBL16206568 | 0.74 | ALDH1A1 (0.38) | ALDH1A1CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL20892175 | 0.74 | AR (0.37) | ALDH1A1KDM4EARPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12508268-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2025-12-30 | — | — | US | disclosed |
| EP-3994125-B1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMA (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20240400556-A1 | AMIDOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240299402-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240285641-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2024-08-29 | — | — | US | disclosed |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| CN-117618423-A | Inhibitors of tryptophan dioxygenase (IDO 1 and TDO) and their use in therapy | 奥克兰联合服务有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117599049-A | Inhibitors of tryptophan dioxygenase (IDO 1 and TDO) and their use in therapy | 奥克兰联合服务有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-11826316-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-11-28 | — | — | US | disclosed |
| US-20230227449-A1 | AMIDOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20140221379-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2014-08-07 | — | — | US | disclosed |
| US-8716303-B2 | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20080194640-A1 | Optically Active Tetrahydronaphthalene Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-14 | — | — | US | disclosed |
| EP-1852431-A1 | OPTICALLY ACTIVE TETRAHYDRONAPHTHALENE DERIVATIVE | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-07 | — | — | EP | disclosed |
| CN-100340548-C | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2007-10-03 | — | — | CN | disclosed |
| EP-1572655-A2 | NOVEL ARYLHETEROALKYLAMINE DERIVATIVES | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| CN-1630637-A | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | CN | disclosed |
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| WO-2002090332-A2 | NOVEL AEYLHETEROALKYLAMINΕ DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | CYP1A1, NOS3, NOS1 | ALDH1A1 495/4885CYP1A2 11/4885CYP2C9 18/4885 |
| US-11826316-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | IDO1, TDO2, IDO2 | ALDH1A1 1167/4885CYP1A2 90/4885CYP2C9 35/4885 |
| US-20240285641-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | IDO1, TDO2, IDO2 | ALDH1A1 1167/4885CYP1A2 90/4885CYP2C9 35/4885 |
| US-20240299402-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | HSD17B3, HSD17B11, HSD17B1 | ALDH1A1 465/4885CYP1A2 808/4885CYP2C9 2455/4885 |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | ALDH1A1 2342/4885CYP1A2 1401/4885CYP2C9 1324/4885 |
| US-20080194640-A1 | Optically Active Tetrahydronaphthalene Derivative | C3AR1, C5AR1, C5AR2 | ALDH1A1 1551/4885CYP1A2 2106/4885CYP2C9 1150/4885 |
| US-12508268-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | IDO1, IDO2, TDO2 | ALDH1A1 732/4885CYP1A2 845/4885CYP2C9 552/4885 |
| US-20230227449-A1 | AMIDOPYRIMIDONE DERIVATIVES | F12, XDH, CYP3A43 | ALDH1A1 1558/4885CYP1A2 32/4885CYP2C9 36/4885 |
| US-11957687-B2 | Modulators of HSD17B13 and methods of use thereof | HSD17B3, HSD17B11, HSD17B1 | ALDH1A1 465/4885CYP1A2 808/4885CYP2C9 2455/4885 |
| US-20140221379-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | ALDH1A1 2342/4885CYP1A2 1401/4885CYP2C9 1324/4885 |
| US-20240400556-A1 | AMIDOPYRIMIDONE DERIVATIVES | F12, XDH, CYP3A43 | ALDH1A1 1558/4885CYP1A2 32/4885CYP2C9 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.